[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed transactions on 08/22/2025 reported on this Form 4. The filing discloses an exercise of a stock option to acquire 30,000 shares at an exercise price of $16.89 per share and an open-market sale of 30,000 shares executed under a Rule 10b5-1 trading plan adopted May 21, 2025.

The sale had a volume-weighted average price of $30.43 per share and a transaction-day price range of $30.00 to $30.98. Following the transactions the reporting person shows 66,270 shares beneficially owned directly and reports 30,000 underlying shares from the option; the Form lists 89,042 derivative securities beneficially owned following the reported transactions. The sale was effected automatically pursuant to the 10b5-1 plan.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating the sale was pre-planned and automated
• Option exercise converted 30,000 options into shares, reflecting realized value for the reporting person

Negative

• Direct beneficial ownership decreased to 66,270 shares following the reported sale
• Sale involved 30,000 shares, which may be perceived by some investors as insider liquidation

Insights

Securities Analyst

TL;DR Insider exercised options and sold shares under a 10b5-1 plan, generating realized proceeds at a VWAP of $30.43.

The reporting shows a routine executive exercise-and-sale on 08/22/2025 by the Chief Medical and Development Officer. The option exercise price of $16.89 versus the sale VWAP of $30.43 indicates a material per-share gain for the reporting person, but the transactions were executed pursuant to a pre-existing 10b5-1 plan which limits interpretation as an information-driven trade. The filing states the sale was automatic and provides the sales price range; no additional company-specific operational or financial disclosures are included.

Corporate Governance Expert

TL;DR This Form 4 documents a compliant, pre-planned insider sale following option exercise; it is a routine governance disclosure.

The Form 4 identifies adherence to Rule 10b5-1 via a plan adopted May 21, 2025, which supports the affirmative defense for automatic sales. Vesting terms for the option are disclosed in the exhibit text, showing time-based vesting with partial vesting beginning 09/30/2023 and monthly installments thereafter. From a governance perspective, the filing provides required transparency but does not signal a change in company strategy or governance structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pizzuti Dana

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med and Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		M		30,000	A	$16.89	96,270	D
Common Stock	08/22/2025		S(1)		30,000	D	$30.43(2)	66,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.89	08/22/2025		M			30,000	(3)	10/10/2032	Common Stock	30,000	$0	89,042	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

	/s/ Tobin Schilke, as attorney-in-fact	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for CRNX and what is their role?

The Form 4 was filed for Dana Pizzuti, who is listed as the Chief Medical and Development Officer of Crinetics Pharmaceuticals.

What transactions did the insider report on 08/22/2025 for CRNX?

The insider exercised 30,000 options at $16.89 and sold 30,000 shares in open-market transactions on 08/22/2025.

At what price were the shares sold and what price range was reported?

The volume-weighted average sale price was $30.43 per share and the sales price range that day was $30.00 to $30.98.

Was the sale part of a 10b5-1 plan for CRNX insider trades?

Yes. The sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025.

How many shares does the reporting person beneficially own after the transactions?

The Form reports 66,270 shares beneficially owned directly after the transactions and discloses 30,000 underlying shares from the option; the filing also lists 89,042 derivative securities beneficially owned following the reported transactions.